Zymeworks financials
$27.20+0.29%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M |
| Gross profit | $106.0M | $76.3M | $76.0M | $412.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$92.5M | -$137.1M | -$138.1M | $130.5M |
| Net income | -$81.1M | -$122.7M | -$118.7M | $124.3M |
| Net margin | −76.6% | −160.8% | −156.1% | 30.1% |
| Diluted EPS | $-1.08 | $-1.62 | $-1.72 | $1.90 |
| EBITDA | -$84.8M | -$111.1M | -$127.9M | $137.8M |
| Operating cash flow | -$33.0M | -$110.1M | -$118.3M | $144.1M |
| Free cash flow | -$34.5M | -$112.0M | -$120.8M | $136.0M |
| Diluted shares | 75.4M | 75.9M | 68.9M | 65.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $41.2M | $66.1M | $157.6M | $400.9M |
| Short-term investments | $187.6M | $159.7M | $216.8M | $91.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $346.5M | $463.1M | $580.9M | $648.7M |
| Total liabilities | $78.0M | $124.3M | $116.1M | $155.8M |
| Shareholders' equity | $268.5M | $338.8M | $464.8M | $493.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology